Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 10, 2025 08:30 ET | Source: Biodexa Pharmaceuticals PLC

Biodexa Announces Successful Outcome of a Type C Meeting with FDA Regarding the Phase 3 Program for eRapa in FAP

March 10, 2025 Biodexa Announces Successful Outcome of a Type C Meeting with FDA Regarding the Phase 3 Program for eRapa in FAP Clears the way to finalize Phase 3 protocol and recruit sites for U.S....
March 29, 2022 09:15 ET | Source: Research Dive

Global Wired Charging Market Anticipated to Generate a Revenue of $14,015.7 Million and Grow at a CAGR of 4.5% during the Analysis Timeframe from 2021-2028 [170-Pages] | Report by Research Dive

New York, USA, March 29, 2022 (GLOBE NEWSWIRE) -- According to a report published by Research Dive, the global wired charging market is envisioned to generate a revenue of $14,015.7 million and rise...
April 14, 2021 08:09 ET | Source: Microchip Technology Incorporated

Open-Source Power Delivery Software Enables Code Integration for USB System Differentiation

CHANDLER, Ariz., April 14, 2021 (GLOBE NEWSWIRE) -- USB Type-C with Power Delivery (PD) and open-source software are two technologies leading the next wave of wired connectivity. With Microchip...
December 23, 2020 07:00 ET | Source: Tarsus Pharmaceuticals, Inc

Tarsus Pharmaceuticals, Inc. Announces Type C Meeting with FDA Regarding NDA Submission Requirements for Lead Candidate TP-03

IRVINE, Calif., Dec. 23, 2020 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), a late clinical-stage biopharmaceutical company whose mission is to discover and deliver breakthrough...
October 30, 2018 09:00 ET | Source: NXP USA, Inc.

NXP’s Game-Changing USB Power Delivery 3.0 End-to-End, Fast Charging Solution Powers ASUS Smart Phone

NXP is first to market with USB PD3.0 compliant, end-to-end fast charging solution for mobile applications EINDHOVEN, The Netherlands, Oct. 30, 2018 (GLOBE NEWSWIRE) -- NXP Semiconductors N.V....
July 17, 2018 07:04 ET | Source: Voyager Therapeutics, Inc.

Voyager Therapeutics Receives FDA Guidance on Development Path for VY-AADC for Parkinson’s Disease and Provides Clinical Update

Voyager continues to plan to submit a BLA for VY-AADC based on its pivotal program and Type C meeting feedback Positive interim results with VY-AADC from the Phase 1 posterior trajectory trial...